|
2025-01-23 |
2025-01-21 |
PS
Planned sale
|
Ezickson Elan
Non-Executive Director
|
1,600
-12.8%
0.54
USD 864
|
1,600
-12.8%
|
0.54
|
USD 864
|
|
|
2025-01-23 |
2025-01-21 |
PS
Planned sale
|
Johnson Marvin
Non-Executive Director
|
1,610
-11.4%
0.54
USD 869
|
1,610
-11.4%
|
0.54
|
USD 869
|
|
|
2025-02-11 |
2024-08-14 |
PP
Planned purchase
|
Braunstein Scott
CHAIRMAN AND CEO
Executive Director
|
5,933
+2.0%
1.10
USD 6,526
|
5,933
+2.0%
|
1.10
|
USD 6,526
|
|
|
2024-08-07 |
2024-08-05 |
PS
Planned sale
|
Braunstein Scott
CHAIRMAN AND CEO
Executive Director
|
12,145
-3.9%
1.13
USD 13,724
|
12,145
-3.9%
|
1.13
|
USD 13,724
|
|
|
2024-08-07 |
2024-08-05 |
PS
Planned sale
|
Hulihan Joseph
CHIEF MEDICAL OFFICER
Officer
|
4,828
-6.2%
1.13
USD 5,456
|
4,828
-6.2%
|
1.13
|
USD 5,456
|
|
|
2024-08-07 |
2024-08-05 |
PS
Planned sale
|
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Officer
|
3,621
-5.7%
1.13
USD 4,092
|
3,621
-5.7%
|
1.13
|
USD 4,092
|
|
|
2024-08-07 |
2024-08-05 |
PS
Planned sale
|
Shafer Christina
CHIEF COMMERCIAL OFFICER
Officer
|
3,820
-5.4%
1.14
USD 4,355
|
3,820
-5.4%
|
1.14
|
USD 4,355
|
|
|
2024-08-07 |
2024-08-05 |
PS
Planned sale
|
Pfanstiel Steven
CFO AND COO
Officer
|
4,657
-5.5%
1.13
USD 5,262
|
4,657
-5.5%
|
1.13
|
USD 5,262
|
|
|
2024-02-22 |
2024-02-20 |
PS
Planned sale
|
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Officer
|
1,894
-3.5%
9.57
USD 18,126
|
1,894
-3.5%
|
9.57
|
USD 18,126
|
|
|
2024-02-22 |
2024-02-20 |
PS
Planned sale
|
Shafer Christina
CHIEF COMMERCIAL OFFICER
Officer
|
2,153
-3.4%
9.56
USD 20,583
|
2,153
-3.4%
|
9.56
|
USD 20,583
|
|
|
2024-02-21 |
2024-02-16 |
PS
Planned sale
|
Pfanstiel Steven
CFO AND COO
Officer
|
3,092
-4.1%
9.97
USD 30,827
|
3,092
-4.1%
|
9.97
|
USD 30,827
|
|
|
2024-02-21 |
2024-02-16 |
PS
Planned sale
|
Hulihan Joseph
CHIEF MEDICAL OFFICER
Officer
|
2,814
-4.1%
9.98
USD 28,084
|
2,814
-4.1%
|
9.98
|
USD 28,084
|
|
|
2024-02-21 |
2024-02-16 |
PS
Planned sale
|
Braunstein Scott
CHAIRMAN AND CEO
Executive Director
|
11,850
-5.0%
9.94
USD 117,789
|
11,850
-5.0%
|
9.94
|
USD 117,789
|
|
|
2023-08-08 |
2023-08-08 |
PS
Planned sale
|
Shafer Christina
CHIEF COMMERCIAL OFFICER
Officer
|
11
-0.0%
8.93
USD 98
|
11
-0.0%
|
8.93
|
USD 98
|
|
|
2023-08-08 |
2023-08-08 |
PS
Planned sale
|
Braunstein Scott
CHAIRMAN AND CEO
Executive Director
|
30
-0.0%
8.94
USD 268
|
30
-0.0%
|
8.94
|
USD 268
|
|
|
2023-08-08 |
2023-08-08 |
PS
Planned sale
|
Pfanstiel Steven
CFO AND COO
Officer
|
14
-0.0%
8.93
USD 125
|
14
-0.0%
|
8.93
|
USD 125
|
|
|
2023-08-08 |
2023-08-08 |
PS
Planned sale
|
Hulihan Joseph
CHIEF MEDICAL OFFICER
Officer
|
13
-0.0%
8.93
USD 116
|
13
-0.0%
|
8.93
|
USD 116
|
|
|
2023-08-08 |
2023-08-08 |
PS
Planned sale
|
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Officer
|
11
-0.0%
8.93
USD 98
|
11
-0.0%
|
8.93
|
USD 98
|
|
|
2023-08-08 |
2023-08-07 |
PS
Planned sale
|
Shafer Christina
CHIEF COMMERCIAL OFFICER
Officer
|
2,385
-5.5%
9.52
USD 22,705
|
2,385
-5.5%
|
9.52
|
USD 22,705
|
|
|
2023-08-08 |
2023-08-07 |
PS
Planned sale
|
Braunstein Scott
CHAIRMAN AND CEO
Executive Director
|
6,413
-3.8%
9.55
USD 61,244
|
6,413
-3.8%
|
9.55
|
USD 61,244
|
|
|
2023-08-08 |
2023-08-07 |
PS
Planned sale
|
Pfanstiel Steven
CFO AND COO
Officer
|
2,790
-5.4%
9.54
USD 26,617
|
2,790
-5.4%
|
9.54
|
USD 26,617
|
|
|
2023-08-08 |
2023-08-07 |
PS
Planned sale
|
Hulihan Joseph
CHIEF MEDICAL OFFICER
Officer
|
2,889
-5.7%
9.55
USD 27,590
|
2,889
-5.7%
|
9.55
|
USD 27,590
|
|
|
2023-08-08 |
2023-08-07 |
PS
Planned sale
|
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Officer
|
2,169
-6.2%
9.54
USD 20,692
|
2,169
-6.2%
|
9.54
|
USD 20,692
|
|
|
2023-02-08 |
2023-02-06 |
PS
Planned sale
|
Fischer Seth H. Z.
Non-Executive Director
|
1,018
-14.5%
6.54
USD 6,658
|
1,018
-14.5%
|
6.54
|
USD 6,658
|
|
|
2023-02-08 |
2023-02-06 |
PS
Planned sale
|
Ezickson Elan
Non-Executive Director
|
750
-11.8%
6.56
USD 4,920
|
750
-11.8%
|
6.56
|
USD 4,920
|
|
|
2023-02-08 |
2023-02-06 |
PS
Planned sale
|
Austin Charles
Non-Executive Director
|
1,073
-16.9%
6.49
USD 6,964
|
1,073
-16.9%
|
6.49
|
USD 6,964
|
|
|
2021-03-16 |
2021-03-15 |
S
Sale
|
VITULLO NICOLE
Non-Executive Director
|
4,250
-100.0%
15.87
USD 67,448
|
4,250
-100.0%
|
15.87
|
USD 67,448
|
|
|
2021-03-11 |
2021-03-09 |
PS
Planned sale
|
Smith Edward F
Former VP, CFO & Treasurer
Officer
|
40,356
-75.2%
17.80
USD 718,337
|
40,356
-75.2%
|
17.80
|
USD 718,337
|
|
|
2020-02-03 |
2020-01-30 |
S
Sale
|
Smith Edward F
CFO
|
2,380
-11.8%
2.05
USD 4,879
|
2,380
-11.8%
|
2.05
|
USD 4,879
|
|
|
2019-12-13 |
2019-12-13 |
B
Purchase
|
Braunstein Scott
Chief Executive Officer
Executive Director
|
100,000
+inf%
1.25
USD 125,000
|
100,000
+inf%
|
1.25
|
USD 125,000
|
|
|
2019-05-20 |
2019-05-16 |
PS
Planned sale
|
Smith Edward F
CFO
Officer
|
24,211
-54.6%
5.03
USD 121,781
|
24,211
-54.6%
|
5.03
|
USD 121,781
|
|
|
2019-01-30 |
2019-01-29 |
S
Sale
|
Smith Edward F
CFO
Officer
|
2,492
-5.3%
3.06
USD 7,626
|
2,492
-5.3%
|
3.06
|
USD 7,626
|
|
|
2019-01-30 |
2019-01-28 |
S
Sale
|
Cashman Christopher Michael
CEO
Executive Director
|
8,142
-3.3%
3.13
USD 25,484
|
8,142
-3.3%
|
3.13
|
USD 25,484
|
|
|
2018-01-29 |
2018-01-29 |
S
Sale
|
Smith Edward F
CFO
Officer
|
3,000
-5.7%
7.91
USD 23,730
|
3,000
-5.7%
|
7.91
|
USD 23,730
|
|
|
2018-01-22 |
2018-01-18 |
S
Sale
|
Cashman Christopher Michael
CEO
Executive Director
|
9,566
-3.7%
6.28
USD 60,074
|
9,566
-3.7%
|
6.28
|
USD 60,074
|
|
|
2017-12-19 |
2017-12-19 |
S
Sale
|
Bain Capital Life Sciences Investors, LLC
Large shareholder
|
55,229
-1.4%
7.11
USD 392,430
|
55,229
-1.4%
|
7.11
|
USD 392,430
|
|
|
2017-12-19 |
2017-12-19 |
S
Sale
|
Bain Capital Life Sciences Investors, LLC
Large shareholder
|
94,771
-2.3%
7.62
USD 722,240
|
94,771
-2.3%
|
7.62
|
USD 722,240
|
|
|
2017-12-19 |
2017-12-18 |
S
Sale
|
Bain Capital Life Sciences Investors, LLC
Large shareholder
|
300,000
-6.8%
7.50
USD 2,251,440
|
300,000
-6.8%
|
7.50
|
USD 2,251,440
|
|
|
2017-12-19 |
2017-12-15 |
S
Sale
|
Bain Capital Life Sciences Investors, LLC
Large shareholder
|
102,882
-2.3%
8.64
USD 888,489
|
102,882
-2.3%
|
8.64
|
USD 888,489
|
|
|
2017-12-19 |
2017-12-15 |
S
Sale
|
Bain Capital Life Sciences Investors, LLC
Large shareholder
|
719,665
-13.7%
8.02
USD 5,770,202
|
719,665
-13.7%
|
8.02
|
USD 5,770,202
|
|
|
2016-10-24 |
2016-10-20 |
S
Sale
|
Mehra Anand
Large shareholder
|
12,528
-44.7%
1.39
USD 17,401
|
12,528
-44.7%
|
1.39
|
USD 17,401
|
|
|
2016-10-24 |
2016-10-20 |
S
Sale
|
Mehra Anand
Large shareholder
|
13,367
-5.6%
1.39
USD 18,567
|
13,367
-5.6%
|
1.39
|
USD 18,567
|
|
|
2016-10-24 |
2016-10-20 |
S
Sale
|
Mehra Anand
Large shareholder
|
724,788
-39.0%
1.39
USD 1,006,731
|
724,788
-39.0%
|
1.39
|
USD 1,006,731
|
|
|
2016-08-09 |
2016-08-08 |
S
Sale
|
Canaan VII LP
Large shareholder
|
19,950
-1.1%
1.50
USD 29,925
|
19,950
-1.1%
|
1.50
|
USD 29,925
|
|
|
2016-08-09 |
2016-08-05 |
S
Sale
|
Canaan VII LP
Large shareholder
|
129,204
-6.5%
1.50
USD 193,806
|
129,204
-6.5%
|
1.50
|
USD 193,806
|
|
|
2016-08-05 |
2016-08-04 |
S
Sale
|
Canaan VII LP
Large shareholder
|
3,329
-0.2%
1.50
USD 4,994
|
3,329
-0.2%
|
1.50
|
USD 4,994
|
|
|
2016-08-05 |
2016-08-03 |
S
Sale
|
Canaan VII LP
Large shareholder
|
142,254
-6.6%
1.50
USD 213,381
|
142,254
-6.6%
|
1.50
|
USD 213,381
|
|
|
2016-08-02 |
2016-07-29 |
S
Sale
|
Canaan VII LP
Large shareholder
|
24,540
-1.1%
1.71
USD 41,963
|
24,540
-1.1%
|
1.71
|
USD 41,963
|
|
|
2016-07-27 |
2016-07-27 |
S
Sale
|
Canaan VII LP
Large shareholder
|
209
-0.0%
1.80
USD 376
|
209
-0.0%
|
1.80
|
USD 376
|
|
|
2016-07-27 |
2016-07-26 |
S
Sale
|
Canaan VII LP
Large shareholder
|
20,380
-0.9%
1.81
USD 36,888
|
20,380
-0.9%
|
1.81
|
USD 36,888
|
|
|
2016-07-26 |
2016-07-25 |
S
Sale
|
Canaan VII LP
Large shareholder
|
137,617
-5.9%
1.86
USD 255,968
|
137,617
-5.9%
|
1.86
|
USD 255,968
|
|
|
2016-07-26 |
2016-07-22 |
S
Sale
|
Canaan VII LP
Large shareholder
|
133,133
-5.4%
1.94
USD 258,278
|
133,133
-5.4%
|
1.94
|
USD 258,278
|
|
|
2016-02-11 |
2015-11-06 |
B
Purchase
|
Cashman Christopher Michael
President and CEO
Executive Director
|
3,561
+3.2%
5.61
USD 19,977
|
3,561
+3.2%
|
5.61
|
USD 19,977
|
|
|
2015-04-23 |
2015-04-21 |
PS
Planned sale
|
Farfel Gail M
Chief Clinical Dev & Reg Offic
Officer
|
30,000
-100.0%
9.48
USD 284,511
|
30,000
-100.0%
|
9.48
|
USD 284,511
|
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Mehra Anand
Non-Executive Director
Large shareholder
|
12,528
+81.0%
8.00
USD 100,224
|
12,528
+81.0%
|
8.00
|
USD 100,224
|
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Mehra Anand
Non-Executive Director
Large shareholder
|
13,367
+5.9%
8.00
USD 106,936
|
13,367
+5.9%
|
8.00
|
USD 106,936
|
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Mehra Anand
Non-Executive Director
Large shareholder
|
724,788
+63.9%
8.00
USD 5,798,304
|
724,788
+63.9%
|
8.00
|
USD 5,798,304
|
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Domain Partners VI, L.P.
Large shareholder
|
419,744
+20.4%
8.00
USD 3,357,952
|
419,744
+20.4%
|
8.00
|
USD 3,357,952
|
|
|
2014-08-06 |
2014-08-05 |
B
Purchase
|
Bloch Stephen M
Non-Executive Director
|
625,000
+34.0%
8.00
USD 5,000,000
|
625,000
+34.0%
|
8.00
|
USD 5,000,000
|
|
|
2014-08-06 |
2014-08-05 |
B
Purchase
|
Canaan VII L P
Non-Executive Director
Large shareholder
|
625,000
+34.0%
8.00
USD 5,000,000
|
625,000
+34.0%
|
8.00
|
USD 5,000,000
|
|
